سعر هيريموز 40مجم/0.8مل 2 سرنجة معبأة 2024

Hyrimoz (adalimumab biosimilar, Sandoz) 40 mg/0.8 ml solution for injection, pack of 2 pre-filled syringes: TNF-alpha blocking monoclonal antibody used for moderate-to-severe inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

• Moderately to severely active rheumatoid arthritisPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Moderately to severely active polyarticular juvenile idiopathic arthritisPopulation: Patients 2 years and olderDailyMed (U.S. National Library of Medicine)
• Active psoriatic arthritisPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning - serious infections: increased risk of serious infections (including active or reactivated tuberculosis, invasive fungal and opportunistic infections) that may lead to hospitalization or death; discontinue if a serious infection or sepsis develops.International label, same product · DailyMed (U.S. National Library of Medicine)
• Boxed warning - malignancy: lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers.International label, same product · DailyMed (U.S. National Library of Medicine)
• Other warnings: hypersensitivity reactions, hepatitis B reactivation, demyelinating disease, cytopenias, new or worsening heart failure, lupus-like syndrome; concomitant abatacept or anakinra not recommended; avoid live vaccines.International label, same product · DailyMed (U.S. National Library of Medicine)

• MethotrexateMethotrexate reduces adalimumab apparent clearance; no dose adjustment of either drug needed.DailyMed (U.S. National Library of Medicine)
• Abatacept, anakinra (biologic products)Increased risk of serious infections without added benefit in RA; combination not recommended.DailyMed (U.S. National Library of Medicine)

• Available studies do not reliably establish an association between adalimumab and major birth defects (OTIS registry: 10% vs 7.5% in disease-matched comparators, no pattern). Adalimumab is actively transferred across the placenta in the third trimester and may affect the infant immune response.International label, same product · DailyMed (U.S. National Library of Medicine)
• Present in human milk at 0.1-1% of maternal serum levels; infant systemic exposure expected to be low; no reported adverse effects on breastfed infants.International label, same product · DailyMed (U.S. National Library of Medicine)

• Adalimumab: Binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell-surface TNF receptors; does not bind lymphotoxin (TNF-beta) (US HYRIMOZ label).